Frontiers in Pharmacology (Apr 2023)

Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review

  • Jia Jing,
  • Li Rui,
  • Sun Junyuan,
  • Yang Jinfeng,
  • Hong Zhihao,
  • Lu Weiguo,
  • Lu Weiguo,
  • Jia Zhenyu

DOI
https://doi.org/10.3389/fphar.2023.1122008
Journal volume & issue
Vol. 14

Abstract

Read online

S-phase kinase-associated protein 2 (Skp2) is a substrate-specific adaptor in Skp1-CUL1-ROC1-F-box E3 ubiquitin ligases and widely regarded as an oncogene. Therefore, Skp2 has remained as an active anticancer research topic since its discovery. Accordingly, the structure of Skp2 has been solved and numerous Skp2 inhibiting compounds have been identified. In this review, we would describe the structural features of Skp2, introduce the ubiquitination function of SCFSkp2, and summarize the diverse natural and synthetic Skp2 inhibiting compounds reported to date. The IC50 data of the Skp2 inhibitors or inhibiting compounds in various kinds of tumors at cellular levels implied that the cancer type, stage and pathological mechanisms should be taken into consideration when selecting Skp2-inhibiting compound for cancer treatment.

Keywords